With this service, we bring the expertise of our medical physicists into your work – whether in routine clinical operations as dosimetry experts for common radiopharmaceutical therapies or in clinical trials exploring new tracers and isotopes.
Contact usThe rapid development of new and innovative radiopharmaceutical therapies requires a personalized approach to maximize treatment outcomes within safety limits and optimize the number of treatment cycles. A patient-specific dosimetry approach is also required for all radiopharmaceutical applications based on the current 2013/59/EURATOM directive (§56).
Our medical physics experts can perform all dosimetry analyses for organs-at-risk and tumors to optimize your treatment outcome.
Whether for established therapies like Lu177-PSMA, Lu177-DOTATE, or Y90-radioembolization, or for research on new tracers – we are your reliable partner. You can find an overview in our service description.
It is essential to accurately calculate the absorbed dose for organs-at-risk. This is the only way to ensure that the dose stays within organ dose limits while maximizing damage to tumors.
Patient-specific calculation of absorbed tumor and organ doses allows you to individually adjust the treatment activity administered and plan the required number of treatment cycles, achieving maximum treatment success.
Accurate protocols for your therapies enable optimal use of your resources and maximum utilization of your PET/CT or SPECT/CT.
Our medical physicists are experts in creating the appropriate imaging protocol for your tomographs, regardless of the manufacturer, for both therapeutic and diagnostic purposes. We also perform calibration factor analysis for you.
First, the imaging protocol is implemented to ensure consistent and reliable imaging procedures. During the calibration process, camera-specific sensitivity factors are determined. The validation of the protocol ensures that all processes meet the required standards and provide reliable data for dosimetry. The precise implementation of the imaging protocol ensures that all imaging procedures are performed consistently and reliably.
Treatment begins with a targeted radiopharmaceutical infusion, followed by post-infusion imaging to monitor the distribution of the agent and ensure effectiveness.
Sequential 2D/3D scans, as well as blood and urine samples, are conducted. The collected data is segmented and converted into time-activity curves. From this, the time-integrated activity coefficients are calculated to quantify radiation exposure. Finally, the absorbed dose for organs-at-risk and tumors is determined.
After dosimetry, a patient-specific report is created, serving as the basis for planning further therapy steps.
Contact usFrom preclinical development to market readiness: our medical physicists accompany you with expertise in all trial phases of your innovative radiopharmaceutical therapy lines.
Create facts with patient-specific dosimetry – and get the most out of your therapy.
With us, you meet the high demands of your radiopharmaceutical trials.
We adapt to your framework conditions.
We bring clear direction to your dosimetry with our expertise.
Oncosia Scientific GmbH
mail@oncosia.de
+49 (0) 160 96255919
© 2025 Oncosia Scientific GmbH. All rights reserved